The Effect of Aprepitant Regimen on the Prevention of High-Dose Cisplatin-Induced Nausea and Vomiting |
Park, Su-Jin
(Department of Pharmacy Service, Samsung Medical Center)
Choi, Ji-Seon (Department of Pharmacy Service, Samsung Medical Center) Ahn, Jin-Seok (Department of Hematology and Oncology, Samsung Medical Center) Shin, Ka-Young (Department of Pharmacy Service, Samsung Medical Center) Min, Kyoung-A (Department of Pharmacy Service, Samsung Medical Center) Chung, Seon-Young (Department of Pharmacy Service, Samsung Medical Center) In, Yong-Won (Department of Pharmacy Service, Samsung Medical Center) Sohn, Kie-Ho (Department of Pharmacy Service, Samsung Medical Center) |
1 | Poli BS, Rodrigues PJ, Carides AD, et al., Aprepitant protocol 054 study group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting, cancer, 2003; 97(12): 3090-3098. DOI ScienceOn |
2 | Andrews PL, Sanger GJ. Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction, Curr Opin Pharmacol 2002; 2: 650-656. DOI ScienceOn |
3 | Oechsle K, Müller MR, Hartmann JT, et al., Aprepitant as salvage therapy in patients with chemotherapy -induced nausea and emesis refractory to prophylaxis with 5- HT3 antagonists and dexamethasone. Onkologie, 2006; 29: 557-561. DOI ScienceOn |
4 | Gan TJ, Apfel CC, Kovac A, et al., A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg, 2007; 104: 1082-1089. DOI ScienceOn |
5 | Jenns K. Importance of nausea. Cancer Nurs, 1994; 17(6): 488-493. |
6 | Van Belle S, Lichinitser MR, Navari RM, et al., Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer, 2002; 94: 3032-3041. DOI ScienceOn |
7 | Warr DG. Chemotherapy-and cancer-related nausea and vomiting. Current Oncology, 2008; 15(1): S4-S9. DOI ScienceOn |
8 | Majumdar AK, Howard L, Goldberg MR et al., Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Journal of Clinical Pharmacology, 2006; 6: 291-230. |
9 | Kris MG, Hesketh PJ, Somerfield MR, et al., American society of clinical oncology guideline for antiemetics in oncology: Update J Clin Oncol, 2006; 24(18): 2932-2947. DOI ScienceOn |
10 | Gralla RJ, Osoba D, Kris MG, et al., Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol, 1999; 16: 1174-1178. |
11 | Hesketh PJ, Grunberg SM, Gralla RJ, et al., The Oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group J Clin Oncol, 2003: 21; 4112- 4119. DOI ScienceOn |
12 | McCrea JB, Majumdar AK, Goldberg MR, et al., Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther, 2003; 74: 17-24. DOI ScienceOn |
13 | Massaro AM, Lenz KL. Aprepitant, a novel antiemetic for chemotherapy -induced nausea and vomiting. Ann Pharmacother, 2005; 39: 77-85. DOI |
14 | Hesketh PJ. New treatment options for chemotherapyinduced nausea and vomiting. Support Care Cancer, 2004; 12: 550-554. |
15 | Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities, Curr Opin Investig Drugs, 2008; 9(7): 774-785. |
16 | Hesketh PJ, Kris MG, Grunberg SM, et al., Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol, 1997; 15: 103-109. DOI |
17 | Van Belle SJ, Cocquvt V. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opin Pharmacother, 2008; 9(18): 3261-3270. DOI ScienceOn |
18 | National comprehensive cancer network clinical practice guideline in oncology TM; Antiemesis V.3., 2008. |
19 | Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med, 2008; 358: 2482-2494. DOI ScienceOn |
20 | Lohr L. Chemotherapy-induced nausea and vomiting. The Cancer Journal, 2008; 14(2): 85-93. DOI ScienceOn |
21 | F. Roila. Prevention of chemotherapy-and radiotherapyinduced emesis: Results of the Perugia consensus conference antiemetic subcommittee of the multinational association of supportive care in cancer (MASCC). Annals of Oncology, 1998; 9: 811-819. DOI ScienceOn |
22 | 김용범 Cisplatin을 포함한 항암화학요법 치료 시 환자에서 발생하는 오심 및 구토에서의 정맥주사용 및 경구용 Tropisetron과 Ondansetron의 비교연구. 대한산부회지, 1998; 41(10): 2544-2550. |
23 | Naeim A, Dy SM, Lorenz KA, et al., Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol, 2008; 26(23): 3901-3910. |